Sachi Sakaguchi
Overview
Explore the profile of Sachi Sakaguchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toi M, Huang C, Im Y, Sohn J, Zhang W, Sakaguchi S, et al.
Cancer Sci
. 2022 Sep;
114(1):221-226.
PMID: 36168844
MONARCH 2 is a global, randomized, double-blind, phase 3 study of abemaciclib/placebo + fulvestrant in patients with hormone receptor positive, human epidermal growth factor receptor 2-negative advanced breast cancer. The...
2.
Inoue K, Masuda N, Iwata H, Takahashi M, Ito Y, Miyoshi Y, et al.
Breast Cancer
. 2021 Apr;
28(5):1038-1050.
PMID: 33797023
Background: This was a Japanese subpopulation analysis of MONARCH 2, a double-blind, randomized, placebo-controlled, phase 3 study of abemaciclib plus fulvestrant in patients with hormone receptor-positive, human epidermal growth factor...
3.
Hiraoka A, Tanizawa Y, Huang Y, Cai Z, Sakaguchi S
Drugs Real World Outcomes
. 2021 Apr;
8(3):301-314.
PMID: 33792850
Background: Evidence about the relationship between albumin-bilirubin (ALBI) grade and sequential systemic therapy for advanced hepatocellular carcinoma in real-world Japanese clinical practice is limited. Objective: The objective of this study...
4.
Kudo M, Ikeda M, Galle P, Yamashita T, Finn R, Liang K, et al.
Hepatol Res
. 2021 Mar;
51(6):715-721.
PMID: 33743189
Aim: The REACH and REACH-2 trials investigated ramucirumab versus placebo in patients with advanced hepatocellular carcinoma (HCC). Ascites is common in HCC and is associated with poorer outcomes. This exploratory,...
5.
Toi M, Inoue K, Masuda N, Iwata H, Sohn J, Park I, et al.
Cancer Sci
. 2021 Mar;
112(6):2381-2392.
PMID: 33686753
This post hoc analysis of MONARCH 2 and MONARCH 3 assesses the efficacy, safety, and pharmacokinetics (PK) of abemaciclib in combination with endocrine therapy (ET) in East Asian patients with...
6.
Chen Y, Noma S, Taguchi Y, Takahashi M, Tsurutani J, Mori S, et al.
Breast Cancer
. 2021 Jan;
28(3):710-719.
PMID: 33453015
Background: This study evaluated characteristics of patients treated with abemaciclib and diagnosed with interstitial lung disease (ILD), using 12-month post-marketing data from the real-world setting in Japan. Methods: Spontaneous reports...
7.
Tamaki C, Hayashi S, Sato A, Maeda K, Sakaguchi S, Buchanan S, et al.
Gan To Kagaku Ryoho
. 2019 Sep;
46(9):1405-1411.
PMID: 31530780
Abemaciclib, a selective cyclin dependent kinases 4 and 6(CDK4 & 6)inhibitor, is under development for the treatment of hormone receptor(HR)-positive, HER2-negative breast cancer. CDK4 & 6 inhibitors attenuate Rb phosphorylation...
8.
Yonemori K, Kodaira M, Satoh T, Kudo T, Takahashi S, Nakano K, et al.
Cancer Sci
. 2018 Oct;
109(12):3962-3970.
PMID: 30353601
Olaratumab, a monoclonal antibody targeting human platelet-derived growth factor receptor α, plus doxorubicin significantly improved overall survival in patients with advanced soft-tissue sarcoma (STS) in a prior phase 1b/2 randomized...
9.
Taga T, Imamura T, Nakashima K, Maeda N, Watanabe A, Miyajima Y, et al.
Int J Hematol
. 2018 Jul;
108(4):438-442.
PMID: 29971602
Myeloid sarcoma (MS) is a rare neoplastic condition that is often described in association with acute myeloid leukemia (AML). MS in childhood has received little attention, particularly in Japan. We...
10.
Sakaguchi S, Higa T, Suzuki M, Fujimura J, Shimizu T
Int J Hematol
. 2017 Mar;
106(2):266-268.
PMID: 28349445
In the present study, we sought to evaluate the prophylactic use of octreotide for asparaginase-induced acute pancreatitis. We reviewed the medical records of seven patients in two institutions who received...